Neuronal nitric oxide synthase is dislocated in type I fibers of myalgic muscle but can recover with physical exercise training by Jensen, L et al.
Syddansk Universitet
Neuronal nitric oxide synthase is dislocated in type I fibers of myalgic muscle but can
recover with physical exercise training
Barner Dalgaard, Line; Andersen, L L; Schrøder, Henrik Daa; Frandsen, Ulrik; Sjøgaard,
Gisela
Published in:
BioMed Research International
DOI:
10.1155/2015/265278
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Jensen, L., Andersen, L. L., Schrøder, H. D., Frandsen, U., & Sjøgaard, G. (2015). Neuronal nitric oxide
synthase is dislocated in type I fibers of myalgic muscle but can recover with physical exercise training. BioMed
Research International, 2015, [265278]. DOI: 10.1155/2015/265278
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Research Article
Neuronal Nitric Oxide Synthase Is Dislocated in Type I Fibers of
Myalgic Muscle but Can Recover with Physical Exercise Training
L. Jensen,1,2 L. L. Andersen,3 H. D. Schrøder,2 U. Frandsen,1 and G. Sjøgaard1
1 Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, 5000 Odense C, Denmark
2Institute of Clinical Research, Pathology and SDUMuscle Research Cluster, University of Southern Denmark,
5230 Odense M, Denmark
3National Research Centre for the Working Environment, 2100 Copenhagen, Denmark
Correspondence should be addressed to L. Jensen; ljensen@health.sdu.dk
Received 15 December 2014; Revised 24 January 2015; Accepted 18 February 2015
Academic Editor: Leonardo F. Ferreira
Copyright © 2015 L. Jensen et al.This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Trapezius myalgia is the most common type of chronic neck pain. While physical exercise reduces pain and improves muscle
function, the underlying mechanisms remain unclear. Nitric oxide (NO) signaling is important in modulating cellular function,
and a dysfunctional neuronal NO synthase (nNOS)may contribute to an ineffective muscle function.This study investigated nNOS
expression and localization in chronically painfulmuscle. Forty-onewomen clinically diagnosedwith trapeziusmyalgia (MYA) and
18 healthy controls (CON) were included in the case-control study. Subsequently, MYA were randomly assigned to either 10 weeks
of specific strength training (SST, 𝑛 = 18), general fitness training (GFT, 𝑛 = 15), or health information (REF, 𝑛 = 8). Distribution of
fiber type, cross-sectional area, and sarcolemmal nNOS expression did not differ between MYA and CON. However, MYA showed
increased sarcoplasmic nNOS localization (18.8± 12 versus 12.8± 8%, 𝑃 = 0.049) compared with CON. SST resulted in a decrease
of sarcoplasm-localized nNOS following training (before 18.1± 12 versus after 12.0± 12%; 𝑃 = 0,027). We demonstrate that myalgic
muscle displays altered nNOS localization and that 10 weeks of strength training normalize these disruptions, which supports
previous findings of impaired muscle oxygenation during work tasks and reduced pain following exercise.
1. Introduction
Musculoskeletal disorders are among the most frequent and
costly health care problems inNorth America and Europe [1].
Work-related neck/shoulder pain, particularly, chronic pain,
tightness, and tenderness of the trapezius muscle, trapez-
ius myalgia, is common in female employees performing
repetitive work tasks [2, 3]. Women with trapezius myalgia
show increased muscle weakness [4, 5] and muscle fatigue
[6]. Trapezius myalgia is associated with various pathological
changes including mitochondrial changes in type I fibers
[7, 8], ragged-red-fibers [9], altered satellite cell distribution
[10], and reduced capillarization per fiber area [7, 8, 11].
Furthermore, numerous studies have shown that trapezius
myalgia is accompanied by poor oxygenation, focal cell death,
and disrupted metabolic homeostasis [8]. Taken together
these data have led to the development of the “Cinderella
theorem,” which proposes that selected type I fibers are the
first to be recruited during repetitive movements at low static
tension and, consequently, these motor units are constantly
activated leading to overload of single muscle fibers [2]. The
theory is supported by the finding of an increased proportion
of hypertrophied type I mega fibers with poor capillarization
[12] and a reduced capillary to fiber area [3] in trapezius
myalgia. Overall, these intramuscular changes create distur-
bances in energy homeostasis and cellular hypoperfusion of
enlarged type I fibers has been suggested as a major factor in
the development of muscle pain [13, 14].
Nitric oxide (NO) is a transient multipurpose signalling
molecule synthesized from oxygen and L-arginine by the
muscle specific neuronal nitric oxide synthase (nNOS) [15–
18]. In m. vastus lateralis, nNOS is anchored at the sarco-
lemma by binding of a PDZ domain to 𝛼1-syntrophin, a
member of the dystrophin-glycoprotein complex (DGC),
and interacting with dystrophin [19, 20]. NO is involved
in regulating satellite cell activation, muscle development,
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metabolism, muscle contraction, and blood flow [21]. Recent
studies indicate that nNOS together with endothelial NOS
(eNOS) is responsible for regulation of microvascular tone
in the muscle [22, 23] and nNOS synthase activity is tightly
controlled by calmodulin and efflux of intercellular Ca++ [24].
Copp and colleagues demonstrated the importance of nNOS-
derived NO during contractions in healthy rat spinotrapezius
muscle using the selective nNOS inhibitor SMTC [25] and the
role of the bioavailability of NOduring recovery from skeletal
muscle contractions using NO donors/inhibitors [26], the
latter supporting a mechanistic link between a reduced NO
availability and prolonged muscle metabolic recovery.
Changes in expression and location of nNOS have been
associated with development of pathogenesis and disease
progression in a number of myopathies and membrane-
associated gene defects [27, 28]. Muscular dystrophies arising
from sarcolemmal defects, like Duchenne muscular dystro-
phy (DMD) and limb-girdle muscular dystrophy (2C, 2D,
and 2E), where the DGC is detached from the sarcolemma,
show loss of nNOS from the sarcolemma [29–31]. More
surprisingly, other forms of non-DGC-related muscular
dystrophies, myopathies, and neuromuscular disorders also
display mislocalization of sarcolemmal nNOS [32, 33]. These
diseases vary in severity but are generally characterized by
progressive muscle loss, increasing weakness, and muscle
fatigue.
Previous data propose that loss of nNOS in DMD give
rise to a dysregulation of vasoconstriction/blood flow [34].
In line with this, Finanger and colleagues suggest that loss
of sarcolemmal nNOS is related to both impaired mobility
and catabolic stress and propose that sarcolemmal nNOS
may be significant in maintaining muscle homeostasis [33].
Studies on the muscle specific nNOS knockout mouse show
that these mice have a lower maximum isometric force and
show increased fatigability [35], and loss of both dystrophin
and nNOS causes impaired control of blood flow during
exercise [36]. In mice, nNOS/NO mediates muscle atrophy
via regulation of FOXO transcription factors and dislocation
of nNOS to the sarcoplasm after disuse-induced studies in the
nNOS-null mice [37]. However, no studies have investigated
the role of these mechanisms in trapezius myalgia.
In healthy muscle, production of NO plays a role in
inhibition of sympathetic vasoconstriction under normal
physiological conditions [38]. As a result of loss of nNOS the
normal protective action of NO against local ischemia during
contraction induced calcium concentrations is ambulated
and an increase in cellular susceptibility to metabolic stress
may be the consequence [34, 39].
The underlying causes of trapezius myalgia and devel-
opment of chronically painful muscles remain unclear, but
multiple studies have demonstrated that strengthening exer-
cises for the neck and shoulders reduce the associated pain
[40–42]. Accordingly, the aim of the present study was to
investigate pathological changes in trapeziusmyalgia that can
help explain the underlying mechanisms of chronic muscle
pain and to reveal possible actions to alleviate such pain.
Specifically, the following hypotheses were tested for women
clinically diagnosed with trapezius myalgia (MYA) com-
pared with healthy controls (CON): (1) MYA patients have
decreased sarcolemma-localized nNOS in type I fibers com-
pared to CON; (2) MYA patients have increased sarcoplasm-
localized nNOS in type I fibers compared to CON; and
(3) strength training normalizes nNOS expression in MYA
toward the level in CON.
2. Materials and Methods
2.1. Study Design and Participants. In the case-control study
42 women clinically diagnosed with trapezius myalgia (MYA
patients: age 44 ± 8 yrs, height 165 ± 6 cm, weight 72 ± 15 kg,
and days with neck pain during previous year 219 ± 19 days)
and 18 healthy controls (CON: age 45±9 yrs, height 167±6 cm,
weight 70 ± 11 kg, and days with neck pain during previous
year 5±6 days) were included. One subject was omitted from
the study prior to analysis due to insufficient biopsy material
resulting in 41 subjects in MYA. All participants were active
in the labour market and recruited from workplaces with
monotonous and repetitive work tasks. Exclusion criteria
were previous trauma, life threatening diseases, whiplash
injury, cardiovascular diseases, or arthritis in the neck and
shoulder. All participants went through a clinical investiga-
tion of the neck and shoulder, performed by trained clinical
personnel, who worked together as a calibrated team as
described in [43]. The main criteria for a clinical diagnosis
of trapezius myalgia were (1) chronic or frequent pain in the
neck area, (2) tightness of the upper trapezius muscle, and (3)
palpable tenderness of the upper trapezius muscle. The CON
group showed no signs of pain in the neck area, tightness
of the upper trapezius muscle, or palpable tenderness of the
upper trapezius muscle.
In the randomized controlled trial (RCT) forty-eight
women with trapezius myalgia were included and random-
ized to one of three 10-week intervention groups: 14 to a
reference group (REF), 18 to specific strength training (SST),
and 16 to general fitness training (GFT). Unfortunately, six
participants dropped out of the REF group after allocation
and inadequate biopsy material was available at baseline for
one subject in REF and for one subject in the GFT and at
followup for 2 subjects in each of the groups GFT and SST.
This resulted in biopsies from 36 women in the study being
analysed in a paired statistical design: 𝑛 = 7 for REF, 𝑛 = 16
for SST, and 𝑛 = 13 for GFT. Further details on the study
group have previously been reported [42].
All participants were informed about the purpose of
the study and gave written informed consent before their
participation. The study was conducted according to the
Declaration of Helsinki and was approved by the local
ethics committee of Copenhagen, Denmark (KF 01-138/04).
Furthermore the study was registered in the International
Standard Randomised Controlled Trial Number Register:
ISRCTN87055459.
2.2. Intervention Protocol. The participants in the RCT were
divided into three groups as described in detail [42]. One
group (SST, 𝑛 = 18) performed high-intensity specific
strength training with five dumbbell exercises for the shoul-
der and neck muscles (one-arm row, shoulder abduction,
shoulder elevation, reverse flyes, and upright row) for 20min
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three times a week. During each session three of the five
different exercises were performed for three sets of each
exercise with relative loadings of 8–12 repetitions maximum
in a periodized and progressive manner. The specificity and
high level of muscle activation of these exercises have been
documented previously [44]. A second group (GFT, 𝑛 = 16)
performed general fitness training on a leg-bicycle ergometer
with relative loadings of 50–70% of the maximal oxygen
uptake for 20min three times a week. The cycling was
performed in an upright position with relaxed shoulders. A
third group (REF, 𝑛 = 8) was not offered any physical training
but received information about health-promoting activities
for a total of 1 h per week.
2.3. Functional Description of Subjects. Results from the case-
control and RCT study on individual pain perception and
muscle function have previously been published. For compar-
ison with the data presented here it should be underlined that
MYA demonstrated in the neck/shoulder area a higher pain
level [45] and lower muscle strength as well as lower muscle
activation based on EMG measures [4, 5] compared with
CON. In the RCT study SST reduced pain (∼80%, 𝑃 < 0.001)
[42], improved muscle strength and activation (peak torque
increased by 18–29%, 𝑃 < 0.01; rate of torque development
increased by 61–115%, 𝑃 < 0.001) [46], improved muscle
endurance, and increased capillarization [6].
2.4. Sample Collection. Muscle biopsies fromMYA and CON
were collected under local anaesthesia (1% lidocaine) with
a Bergstrom biopsy needle from the upper trapezius muscle
at the midpoint between the 7th cervical vertebra and the
acromion. The exact biopsy site was determined by inspec-
tion with ultrasonography. Approximately 50mg tissue was
excised, quickly dissected from fat and connective tissue;
fibres were aligned, embedded in Tissue-Tek (Sakura Finetek
Europe, Zoeterwoude, Netherlands), and frozen in precooled
isopentane. Samples were stored at –80∘C.Onemuscle biopsy
collected from the vastus lateralis of a healthy control subject
was treated and stored as described above and was used as
comparison for the nNOS staining. All biopsy samples were
assigned a unique identification number, thus blinding the
investigator to the participant’s identity. Transverse sections
(10 𝜇m)were cut at –24∘Cusing a cryostat and picked up onto
SuperFrost Plus glass slides (Menzel-Gla¨ser, Braunschweig,
Germany). Biopsies were stained in batches, arranged by an
investigator not involved in the analysis, such that each batch
contained biopsies from all 3 groups and the samples before
and after training from the same individuals.
2.5. Histochemical Staining
Diaphorase Activity. nNOS activity was evaluated by nicoti-
namide adenine dinucleotide phosphate-tetrazolium reduc-
tase staining (NADPH-TR) as described previously [20].
Sections of frozen tissue were fixed in freshly prepared 4%
paraformaldehyde before they were incubated with NADPH-
TR solution (nitroblue tetrazolium 0.2mM (Sigma) and 𝛽-
NADPH 1mM (Sigma) in Tris buffer 0.2M with 0.25% triton
X-100, pH 7.3, sterile filtered) for 60min at 37∘C, washed in
Tris buffer 0.02M pH 7.4, andmounted in aqueousmounting
medium (Vector Laboratories, VWR, Herlev, Denmark).
NADHOxidase Activity. Nicotinamide adenine dinucleotide-
tetrazolium reductase (NADH-TR) stains were performed
according to standard procedures. Briefly, frozen sections
were incubated with NADH-TR solution (nitroblue tetra-
zolium 2mM (Sigma) and NADH 1mM (Sigma) in Tris
buffer 0.02M pH 7.4, sterile filtered) for 45min at 37∘C and
washed in Tris buffer 0.02M pH 7.4 and H
2
O followed by
10min incubationwith calciumchloride in 4% formaldehyde.
The sections were washed in H
2
O and fixed in acetone before
aqueous mounting.
2.6. Immunohistochemical Staining. Sections of frozen tissue
were fixed in 4% normal buffered formalin and blocked in
Protein Block (Dako, Denmark) before they were incubated
with primary antibodies 1 h at RT. For the nNOS/MHC-
II staining, the same batches of primary and secondary
antibodies were used for all sections. Primary antibodies for
myosin heavy chain II (MHC-II) (1 : 2000, M4276, Sigma
Aldrich, Denmark), nNOS (1 : 200, AF2416, R&D Systems,
United Kingdom), myosin heavy chain I (MHC-I) (1 : 2000,
M8421, Sigma Aldrich, Denmark), 𝛼-dystroglycan (1 : 50,
clone VIA4-1, Millipore, Germany), dystrophin (rod, 1 : 10,
MAB1692, Millipore, Germany; C-terminal, 1 : 5, MAB1694,
Millipore, Germany; N-terminal, 1 : 20, clone 34C5, Novo-
castra, United Kingdom), or laminin (polyclonal, Z0097,
Dako, Denmark) were used. Alexa Fluor 488 or 555 don-
key anti-mouse (1 : 1000, Molecular Probes; Invitrogen A/S,
Denmark), 555 rabbit anti-goat (1 : 1000, Molecular Probes;
Invitrogen A/S, Denmark), or 350 donkey anti-rabbit (1 : 500,
Molecular Probes; Invitrogen A/S, Denmark) were used as
secondary antibodies, while 4󸀠,6-diamidino-2-phenylindole
(DAPI) in themountingmedium (Molecular Probes ProLong
Gold antifade reagent, Invitrogen)was used to stain the nuclei
blue. The fiber specificity of MHC-I and MHC-II antibodies
was evaluated to ensure specificity to type I and type II fibers,
respectively. Images can be found in Supplementary Material
(Figure S1) (see Supplementary Materials available online at
http://dx.doi.org/10.1155/2015/265278).
2.7. Image Collection and Data Analysis. Randomly, three
distinct images were collected from each section stained
with MHC-II/nNOS using Axio Imager 1 equipped with
AxioVision 4.6 software at identical exposure settings allow-
ing a direct comparison between sections. For each image
the cross-sectional area (CSA) and total number of fibres
were determined. The relative number of type II fibres on
each section was quantified by counting the number of type
II+ fibres and expressing this number relative to the total
number of muscle fibres. Additionally, semiquantitative anal-
ysis of sarcolemma-localized nNOS intensity was performed
by grouping each fibre into three categories after visual
inspection and describing the fibres as no or very little nNOS
expression (nNOS−), reduced expression (nNOS+), or nor-
mal expression (nNOS++) and likewise expressing each group
relative to the total number of muscle fibres. For each subject,
the CSA of the fibres belonging to nNOS− was determined
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Table 1: Quantification of immunohistochemical stainings.
Fiber type percentage (%) nNOS intensity (%) Cross-sectional area (𝜇m2)
Type I Type II nNOS− nNOS+ nNOS++ nNOSsp Average nNOS− fibers
CON 𝑛 = 18 63.3 ± 11 36.7 ± 11 25.3 ± 7 24.4 ± 8 50.2 ± 8 12.8 ± 8 5166 ± 1026 5950 ± 1309b
MYA 𝑛 = 41 65.8 ± 11 34.2 ± 11 26.4 ± 10 27.2 ± 14 46.4 ± 12 18.8 ± 12a 5149 ± 997 6104 ± 1415b
REF 𝑛 = 7
Before 63.0 ± 10 37.0 ± 10 20.1 ± 7 39.4 ± 25 40.5 ± 18 15.4 ± 9 5362 ± 629 5995 ± 505b
After 64.1 ± 15 35.9 ± 15 28.6 ± 8 30.0 ± 17 41.3 ± 14 14.1 ± 10 5221 ± 989 6783 ± 1556b
GFT 𝑛 = 13
Before 67.2 ± 11 32.8 ± 11 31.5 ± 11 26.6 ± 11 41.9 ± 13 17.0 ± 11 5362 ± 525 6215 ± 1776b
After 65.6 ± 13 34.4 ± 13 30.8 ± 12 26.9 ± 11 42.9 ± 13 13.1 ± 14 5249 ± 1935 6106 ± 1437b
SST 𝑛 = 16
Before 66.0 ± 12 34.0 ± 12 22.4 ± 7 24.8 ± 7 52.9 ± 7 18.1 ± 12 4956 ± 1417 6211 ± 1489b
After 64.3 ± 13 35.7 ± 12 23.7 ± 9 25.9 ± 9 50.4 ± 9 12.0 ± 12c 5300 ± 1805 6123 ± 1192b
aSignificant increase in nNOSsp in MYA compared to CON (𝑃 < 0.05). bSignificant increase in CSAnNOS- compared to CSAavarage (𝑃 < 0.01). cSignificant
decrease from before to after training (𝑃 < 0.05).
No nNOS in the sarcolemma (nNOS−), reduced nNOS in the sarcolemma (nNOS+), normal nNOS in the sarcolemma (nNOS++), and nNOS in the sarcoplasm
(nNOSsp).
(CSA(nNOS−)) and the total number of fibres showing nNOS
staining in the sarcoplasm was quantified (nNOSsp) and
expressed relative to the total number of muscle fibres. For
the remaining staining representative images were collected.
2.8. Validation and Statistics. The investigator collecting the
biopsy images and performing the analyses was blinded
to experimental setup and a fraction of the biopsies were
analysed twice to ensure consistency in counting and anal-
ysis. Subsequently, the data were unblinded and statistically
analysed using paired (RCT) or unpaired (case-control) t-test
in GraphPad Prism 5. Statistical significance was accepted at
an alpha level of 0.05. Data are presented as mean ± standard
deviations (SD) unless stated otherwise.
3. Results
The number of fibers counted per subject was 292+/− 43
(MYA) and 302+/− 82 (CON). No difference was observed in
distribution of type I/II fibers and mean CSA between MYA
patients and CON (Table 1). NADPH diaphorase activity
staining of trapezius muscle revealed lower nNOS activity
in the sarcolemma and higher activity in the sarcoplasm of
type I fibers compared to type II fibers (Figure 1(a)). Based
on evaluations of immunohistochemical staining of nNOS
from all subjects, approximately 50% of the muscle fibers
in both MYA and CON showed either loss of (nNOS−) or
reduced amounts of (nNOS+) sarcolemmal-localized nNOS
(Table 1; Figure 1(b)). The remaining 50% of muscle fibers
expressed normal levels of nNOS (nNOS++). Notably, an
increased proportion of fibers in MYA presented with nNOS
protein localized to the sarcoplasm compared to CON (18.8±
12 versus 12.8 ± 8%, 𝑃 = 0.049) (Table 1 and Figure 2).
For purposes of comparison with trapezius muscle an image
of nNOS expression in healthy vastus lateralis muscle is
included (Figure 1(b)).
Histochemical and immunohistochemical staining on
serial sections for NADPH diaphorase activity, dystrophin
(rod domain), MHC-I, laminin, and nNOS revealed normal
dystrophin expression in type I fibers with loss of nNOS
activity and loss of sarcolemmal nNOS protein (Figure 3).
Staining for 𝛼-dystroglycan and N- and C-terminal domains
of dystrophin revealed a similar pattern (images not shown).
NADH-TR staining showed alterations in the intermy-
ofibrillar network and clustering of cellular material in the
sarcoplasm of some type I muscle fibers. Most of these same
fibers showed loss of sarcolemmal nNOS (Figure 4).
Although the distribution of fibers belonging to nNOS−,
nNOS+, or nNOS++ was not found to be different between
MYA and CON (Table 1), it was observed that all fibers in
nNOS− were of type I (Figure 1). Moreover, the CSA of fibers
in nNOS− (CSAnNOS−) was significantly larger compared to
the average CSA (CSAaverage) in both MYA and CON (CON:
5166±1026 versus 5950±1309 𝜇m2; MYA: 5149±997 versus
6104 ± 1415 𝜇m2, 𝑃 < 0.01, Table 1 and Figure 1).
The randomized controlled trial study showed that 10
weeks of muscle training altered the nNOS expression. The
group performing SST showed a significant decrease in
sarcoplasm-localized nNOS after 10 weeks of training (before
18.1 ± 12 versus after 12.0 ± 12%; 𝑃 = 0, 027), while GFT
(before 17.0 ± 11 versus after 13.1 ± 14%; 𝑃 = 0.27) and REF
(before 15.4 ± 9 versus after 14.1 ± 10%; 𝑃 = 0.70) did not
change (Figure 5).
4. Discussion
The major finding of this study is a decreased sarcolemmal
nNOS expression of distinctive type I fibers in the trapez-
ius muscle of women with repetitive work tasks. Further,
women suffering from trapezius myalgia showmore frequent
localization of nNOS to the sarcoplasm compared to healthy
controls and this sarcoplasmic localization can be reversed by
specific strengthening exercises.
Trapezius muscle in women with repetitive work tasks
(both with and without neck pain) displays a distinct loss
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Figure 1: Altered nNOS activity and protein expression. (a) Assessment of NOS activity in trapezius muscle from women with repetitive
work tasks (MYA patients and CON) shows loss of activity in sarcolemma and gain of activity in sarcoplasm of large type I fibers compared
to type II. Serial sections show NOS activity in black and MHC-I in red. # marks identical fibers on serial sections. Scale bar: 50 𝜇m. (b)
Immunohistochemical staining of nNOS and MHC-II from trapezius and vastus lateralis muscle. In trapezius muscle type I fibers show
reduced sarcolemma-localized nNOS protein and greater sarcoplasmic nNOS protein (∗) compared with type II fibers. Vastus lateralis did
not show this type of alterations. nNOS in red, myosin heavy chain II in green, and amerged image with DAPI in blue. I and II mark identical
type I and type II fibers, respectively. Scale bar: 50 𝜇m.
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Figure 2: Trapezius myalgia shows sarcoplasm-localized nNOS.
Data from the case-control study showed an increased proportion
of muscle fibers with nNOS protein localized in the sarcoplasm
in trapezius myalgia (MYA) patients compared to healthy controls
(CON) detected by immunohistochemistry. 18.8 ± 12 versus 12.8 ±
8%, 𝑃 = 0.049.
of sarcolemma-localized nNOS in approximately one quarter
of the muscle fibers (Table 1), which is unlike the nNOS
pattern seen in healthy biopsies collected from m. vastus
lateralis, where all fibers show clear and similar staining
[47, 48]. Loss or disruption of sarcolemmal nNOS expression
has earlier been detected in patients with various neuro-
muscular diseases and is in general correlated with disease
progression [27–30, 33, 49, 50]. Previous data propose that
loss of sarcolemmal nNOS in DMD leads to a dysregula-
tion of vasoconstriction [34, 35] or is related to impaired
mobility and catabolic stress and that nNOS is necessary for
maintaining muscle homeostasis [33, 35]. It has been shown
that alpha-adrenergic vasoconstriction was greatly impaired
in the contracting muscles of the 𝛼-syntrophin null mice
[51] and that reduced sarcolemmal nNOS exacerbates the
fatigue experienced after mild exercise because the normal
contraction induced decrease in local vasoconstriction is
disrupted [32]. Further, nNOS has been shown to regulate
basal microvascular tone in humans [52] and knockout of
muscle specific nNOS in mice caused reductions in maxi-
mum tetanic force and increased susceptibility to contraction
induced fatigue [35]. Together, these results support a role
of nNOS in local vasoconstriction and development of func-
tional ischemia and metabolic stress in the trapezius muscle
during contraction and disruption of nNOS expressionmight
subsequently play a role in development of work-related
chronic muscle damage.
Previous analyses of fibers from the present subjects
revealed the presence of type Imega fibers in trapeziusmuscle
[12], defined as type I fibers being at least twice the size of
the median type I muscle fiber size for each individual. In the
present study, it is demonstrated that sarcolemma-localized
nNOS ismissing in enlargedmuscle fibers.Moth-eaten fibers,
which are evidence of intermyofibrillar network alterations,
that is, changes in sarcoplasmic reticulum and mitochondria
localization, have previously been found to have an increased
CSA in the trapezius muscle [53]. In support of this finding,
we observe that a great fraction of themoth-eaten fibers show
disruption of sarcolemmal nNOS expression, thus implying
that interrupted mitochondrial function and impaired local
NO production and regulation occur specifically in enlarged
type I fibers in the trapezius muscle of women with repetitive
work tasks. Whether nNOS dislocation in large type I fibers
is a result of muscle fiber hypertrophy caused by prolonged
low force static work leading to functional ischemia and focal
death or myofibrillar network changes and loss of sarcolem-
mal nNOS causing ischemia during low force static work and
eventually inducing hypertrophy remains unknown.
In the present study, more frequently dislocation of
nNOS to the sarcoplasm is observed in MYA patients com-
pared to CON. This is contrary to a previous study, which
found no difference in nNOS expression using whole mus-
cle homogenate and western blotting analysis comparing
fibromyalgia and controls [54]. The discrepancy may arise
from difference in pathophysiology of the diseases and is
further explained by increased ability and thus sensitivity
to identify nNOS in specific locations using histochemistry
and immunohistochemistry methods of detection as used
in the present study. Previous studies imply that dislocation
of nNOS and the following disruption of local NO produc-
tion increase oxidative stress, glycosylate and/or nitrosylate
the skeletal muscle ryanodine receptor (RYR1), and alter
sarcoplasmic calcium release, which induces protein degra-
dation and activation of calpains. Increased stress-related
mRNA and protein [55] and decreased oxygenation [56]
have been identified in the present study cohort and impli-
cate functional defects. Dislocation of nNOS from the sar-
colemmawill leave unanchored nNOS floating around inside
the cell, which is in agreement with our observations of sar-
coplasmic nNOS.This sarcoplasmic localization is thought to
increase the presence of reactive oxygen and nitrogen species
(ROS/RNS) [47], and the present observation of alterations
in intermyofibrillar network and a subsarcolemmal increase
and/or clustering of mitochondria along the fiber membrane
of type I fibers further supports this notion as mitochondria
are amajor source of ROS [57]. In combination, the increased
size of type I fibers and thus increased diffusion distance
leading to functional ischemia and the increased ROS/RNS
might lead to modifications of proteins and overall tissue
damage. Mutations in RYR1 gene leading to a defective RYR1
have been shown to cause neuromuscular disease and studies
have shown an association between mutations in RYR1
causing disruptions in sarcoplasmic calcium regulation and
development of unexplained rhabdomyolysis and/or exer-
tional myalgia [58–60]. Further, several experiments indicate
a relationship between muscle weakness and nitrosylation
of RYR1 in muscular dystrophies [50, 61] and in the heart
[62] stressing the importance of a tightly controlled NO pro-
duction to maintain calcium homeostasis and correct muscle
function. We found a normal expression and localization of
dystrophin indicating maintained membrane integrity and
ruling out disrupted membrane anchoring of dystrophin as
the reason for dislocation of nNOS as seen in DMD.
Some of the early studies on trapezius myalgia found a
link between a reduction in blow flow and an increase in
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Figure 3: Intact dystrophin protein of type I fibers. Serial sections reveal normal dystrophin and laminin sarcolemmal protein expression in
type I fibers displaying loss of NOS activity and reduced nNOS protein. NOS activity in black, dystrophin in white, laminin in blue, MHC-I
in green, and nNOS in red. ∗marks identical fibers on serial sections. Scale bar: 100 𝜇m.
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Figure 4: Intermyofibrillar network changes in muscle fibers lacking sarcolemmal nNOS. Enlarged type I fiber (#) with decreased
sarcolemmal nNOS protein shows alterations in the intermyofibrillar network demonstrated by irregular NADH-TR staining ((a) and (b):
arrow head). Note also a subsarcolemmal accumulation of cellular material or mitochondria seen as dark areas below the fiber membrane
((b): dark arrow). Type II fibers appear normal. NADH-TR (mitochondria) is blue, MHC-I is green, and nNOS is red. # marks identical fibers
on serial sections. Scale bar: 50𝜇m.
muscle pain [63] and this observation has been supported
and extended by others since then. Women with myalgia
have lower muscle oxygenation, higher muscular lactate, and
lower anaerobic threshold compared to controls [3, 7, 9, 11,
14, 53, 56, 64]. Multiple studies have found exercise training
to reduce work-related pain in the neck and shoulder [65–
68], including subjects from the present study cohort. The
present data show a significant reduction in sarcoplasmic
8 BioMed Research International
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Figure 5: Effect of exercise on sarcoplasm-localized nNOS. The randomized controlled trial revealed that specific strength training (SST)
caused a decrease in sarcoplasm-localized nNOS protein after 10 weeks of training ((a): before 18.1 ± 12 versus after 12.0 ± 12%; 𝑃 = 0, 027),
while the group doing general fitness training (GFT) ((b): before 17.0 ± 11 versus after 13.1 ± 14%; 𝑃 = 0.27) and the reference group (REF)
((c): before 15.4 ± 9 versus after 14.1 ± 10%; 𝑃 = 0.70) did not change.
nNOS after SST. Further, SST also induced an increased
capillarization, which likely also plays a role to increase
blood flow and decrease pain [6, 12]. Previously, an associ-
ation between nNOS and impaired mobility status has been
detected in neuromuscular conditions [33], but the specific
function of nNOS in exercising trapezius myalgia has not
been investigated. A role for NO in exercise intolerance and
impaired microcirculation has been suggested [25, 26, 69],
and we have added to this theory based on results from the
present study population. Together, they highlight the need
for additional investigations particularly regarding the role of
nNOS localization and local NO production in work-related
muscle pain.
5. Conclusion
We showed that sarcolemmal nNOS expression is irregular
and absent from selected fibers in the trapeziusmuscle.More-
over, we found an increase in sarcoplasm-localized nNOS
in women with trapezius myalgia, which was essentially
normalized by 10 weeks of specific strength training. Abnor-
malities in nNOS expression show a potential of predicting
the progression of muscle damage and pain, and correcting
the dislocation of nNOS may prove essential in treatment of
work-related muscle pain as well as other muscle diseases.
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